Gapping up
In reaction to strong earnings/guidance: AMKR +19.7%, ARO +16.3%, (Aeropostale raises guidance, announces two executive appointments), SYN +7.8%, RLD +7%, CMP +6.9%, URBN +6.8%, (reports Q4 revs $1.01 bln vs $998.36 mln Capital IQ Consensus Estimate; Comparable Retail segment net sales, which include comparable direct-to-consumer channel, increased 6%), CGEN+6.3%, QLYS +5.8%, UNIS +5.7%, HOT +5.6%, NSP +5.4%, TDW +5.3%, NEWP +4.8%, FONR +4.7%, KO +4.3%, MPO +3.8%, SFUN +3.5%, GIG +3.4%, NTES +3.3%, SEE +3.3%, WYN +3.1%, QCOM +2.7%, (reaches a resolution with China's National Development and Reform Commission regarding its investigation of Qualcomm under China's Anti-Monopoly Law; co fined $975 mln and raises low end of FY15 guidance), ARWR +2.7%, ALLT +2.7%, CDW +2.6%, AMAG +2.5%, SAVE +2%, CRK +1.5%, IMN +1.2%, NGL +1.1%, MOH +1%
M&A news: KMI +0.9% (to purchase three Vopak U.S. terminals and one undeveloped site for $158 Million)
Select EU financial related names showing strength: NBG +6.2% (volatility surrounding Greece/EU), BBVA +2.1%, IRE +1.3%, SAN +1%, CS +1%
Other news: XGTI +31% (announces $1 mln purchase agreement with Townes Tele-Communications), XON +9.3% (Synthetic Biologics, in collaboration with Intrexon (XON) announces positive topline results from Phase 1b Trial of SYN-004), SYN +7.8% (announces positive topline results from Phase 1b Trial of SYN-004), RLD +7% (announced it has engaged Moelis & Company LLC as its financial advisor to assist in its evaluation of potential strategic alternatives; co also reported earnings), MNOV +2.5% (FDA has approved the protocol for a clinical trial of MN-001 for the treatment of moderate to severe IPF), ACHN +2.5% (cont strength), IBN +2.3% (Sensex strong overnight), TSM +2.1% (reported Jan sales; Board of Directors today adopted a proposal recommending distribution of a NT$4.5 cash dividend per common share), SUNE +2.1% (announces an agreement with PermaCity to develop, build and operate 22 megawatts of rooftop solar as part of the Beacon Bundled Solar contract), TTM +1.7% (sensex strong overnight), MU +1.4% (co and Inotera Memories entered into a supply agreement that amends and restates the existing supply agreement, and a new supply agreement, to take effect as of January 1, 2016), FENG +0.9% (increases strategic investment in Yidian), BABA +0.9% (and Ant Financial announce completion of restructuring)
Analyst comments: CYBR +4.3% (upgraded to Outperform from Market Perform at William Blair), C +1.7% (upgraded to Buy from Hold at Deutsche Bank), BLK +1.7% (target raised to $415 from $405 at BofA/Merrill; Buy -- Added to US 1 List), PTX +1.6% (initiated with a Buy at Cantor Fitzgerald), CRH +1.4% (upgraded to Add at Numis), STJ +1% (upgraded to Buy from Neutral at Sterne Agee), MOS +1% (upgraded to Overweight from Neutral at HSBC Securities), LULU +0.9% (target raised to $70 from $68 at Oppenheimer)
In reaction to strong earnings/guidance: AMKR +19.7%, ARO +16.3%, (Aeropostale raises guidance, announces two executive appointments), SYN +7.8%, RLD +7%, CMP +6.9%, URBN +6.8%, (reports Q4 revs $1.01 bln vs $998.36 mln Capital IQ Consensus Estimate; Comparable Retail segment net sales, which include comparable direct-to-consumer channel, increased 6%), CGEN+6.3%, QLYS +5.8%, UNIS +5.7%, HOT +5.6%, NSP +5.4%, TDW +5.3%, NEWP +4.8%, FONR +4.7%, KO +4.3%, MPO +3.8%, SFUN +3.5%, GIG +3.4%, NTES +3.3%, SEE +3.3%, WYN +3.1%, QCOM +2.7%, (reaches a resolution with China's National Development and Reform Commission regarding its investigation of Qualcomm under China's Anti-Monopoly Law; co fined $975 mln and raises low end of FY15 guidance), ARWR +2.7%, ALLT +2.7%, CDW +2.6%, AMAG +2.5%, SAVE +2%, CRK +1.5%, IMN +1.2%, NGL +1.1%, MOH +1%
M&A news: KMI +0.9% (to purchase three Vopak U.S. terminals and one undeveloped site for $158 Million)
Select EU financial related names showing strength: NBG +6.2% (volatility surrounding Greece/EU), BBVA +2.1%, IRE +1.3%, SAN +1%, CS +1%
Other news: XGTI +31% (announces $1 mln purchase agreement with Townes Tele-Communications), XON +9.3% (Synthetic Biologics, in collaboration with Intrexon (XON) announces positive topline results from Phase 1b Trial of SYN-004), SYN +7.8% (announces positive topline results from Phase 1b Trial of SYN-004), RLD +7% (announced it has engaged Moelis & Company LLC as its financial advisor to assist in its evaluation of potential strategic alternatives; co also reported earnings), MNOV +2.5% (FDA has approved the protocol for a clinical trial of MN-001 for the treatment of moderate to severe IPF), ACHN +2.5% (cont strength), IBN +2.3% (Sensex strong overnight), TSM +2.1% (reported Jan sales; Board of Directors today adopted a proposal recommending distribution of a NT$4.5 cash dividend per common share), SUNE +2.1% (announces an agreement with PermaCity to develop, build and operate 22 megawatts of rooftop solar as part of the Beacon Bundled Solar contract), TTM +1.7% (sensex strong overnight), MU +1.4% (co and Inotera Memories entered into a supply agreement that amends and restates the existing supply agreement, and a new supply agreement, to take effect as of January 1, 2016), FENG +0.9% (increases strategic investment in Yidian), BABA +0.9% (and Ant Financial announce completion of restructuring)
Analyst comments: CYBR +4.3% (upgraded to Outperform from Market Perform at William Blair), C +1.7% (upgraded to Buy from Hold at Deutsche Bank), BLK +1.7% (target raised to $415 from $405 at BofA/Merrill; Buy -- Added to US 1 List), PTX +1.6% (initiated with a Buy at Cantor Fitzgerald), CRH +1.4% (upgraded to Add at Numis), STJ +1% (upgraded to Buy from Neutral at Sterne Agee), MOS +1% (upgraded to Overweight from Neutral at HSBC Securities), LULU +0.9% (target raised to $70 from $68 at Oppenheimer)